
|Articles|December 25, 2022
Most-Read Conference Coverage of 2022
Author(s)Briana Contreras
Conference season was a busy one this year with many stories to come out each one MHE covered. The most-read conference stories from our audience began with Atopic Dermatitis treatment at AMCP to discussion series with PBM leader Alan Lotvin of CVS Caremark.
Advertisement
- AMCP 2022: Atopic Dermatitis Treatment is a Good News Story, Say Symposium Panelists
Dupixent (dupilumab) ushered in a new era and a growing number of treatment options has brought awareness to the condition. But the panelists also discussed problems with step therapy, delays and denials of treatment and the lack of a “gold standard” test for diagnosis.Read more - Weight-Loss Drugs: Why This Time It May Be a Different Story | 2022 PBMI Annual National Conference
The harm caused by weight-loss drugs have overwhelmed any benefit they may have. The repurposed diabetes drugs like Wegovy (semaglutide) have a strong safety profile, said presented at the annual Pharmacy Benefit Management Institute meeting.Read more - Specialty Pharmacy Controls Limit Patient Access, Fein and Long Explain: 2022 Asembia Specialty Pharmacy Summit
In their general session, Adam J. Fein, PhD of Drug Channels Institute, and Doug Long of IQVIA reviewed the current specialty pharmacy space, ongoing trends and future expectations.Read more - 2022 PBMI National Meeting Kicks Off Monday
Agenda includes sessions on overall trends in the pharmacy benefit management industry, digital therapeutics and biosimilars.Read more - A Conversation with Alan Lotvin, M.D. on the PBM Industry’s Reputation | Part 1
The president of CVS Caremark discusses the PBM industry’s reputation, list prices and rebates.Read more
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
What Health Plans Should Ask For in Their PBM Contracts If They Want Transparency | AMCP Nexus 2025
2
Nonfactor agents for hemophilia prophylaxis: A Q&A with Steven Pipe, M.D.
3
Automated Prior Authorization Speeds Approval of GLP-1 Therapies | AMCP Nexus 2025
4
Nonfactor Therapies for Hemophilia: Current Evidence, Clinical Relevance and Cost Considerations
5

















































